ALSUntangled #74:Withania Somnifera (Ashwagandha).

Sartaj Jhooty, Paul Barkhaus, Andrew Brown, Javier Mascias Cadavid, Gregory T Carter, Jesse Crayle, Terry Heiman-Patterson, Xiaoyan Li, Elise Mallon, Christopher Mcdermott, Tasnim Mushannen, Gary Pattee, Dylan Ratner, Paul Wicks, Martina Wiedau, Richard Bedlack
{"title":"ALSUntangled #74:Withania Somnifera (Ashwagandha).","authors":"Sartaj Jhooty, Paul Barkhaus, Andrew Brown, Javier Mascias Cadavid, Gregory T Carter, Jesse Crayle, Terry Heiman-Patterson, Xiaoyan Li, Elise Mallon, Christopher Mcdermott, Tasnim Mushannen, Gary Pattee, Dylan Ratner, Paul Wicks, Martina Wiedau, Richard Bedlack","doi":"10.1080/21678421.2024.2311721","DOIUrl":null,"url":null,"abstract":"<p><p>ALSUntangled reviews alternative and off-label treatments on behalf of people with ALS (PALS) who ask about them. Here, we review withania somnifera (WS) commonly known as ashwagandha or winter cherry. WS has plausible mechanisms for slowing ALS progression because of its effects on inflammation, oxidative stress, autophagy, mitochondrial function, and apoptosis. Preclinical trials demonstrate that WS slows disease progression in multiple different animal models of ALS. Of the five individuals we found who described using WS for their ALS, two individuals reported moderate benefit while none reported experiencing any significant side effects. There is currently one clinical trial using WS to treat PALS; the results are not yet published. There are no serious side effects associated with WS and the associated cost of this treatment is low. Based on the above information, WS appears to us to be a good candidate for future ALS trials.</p>","PeriodicalId":72184,"journal":{"name":"Amyotrophic lateral sclerosis & frontotemporal degeneration","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"ALSUntangled #74: Withania Somnifera (Ashwagandha).\",\"authors\":\"Sartaj Jhooty, Paul Barkhaus, Andrew Brown, Javier Mascias Cadavid, Gregory T Carter, Jesse Crayle, Terry Heiman-Patterson, Xiaoyan Li, Elise Mallon, Christopher Mcdermott, Tasnim Mushannen, Gary Pattee, Dylan Ratner, Paul Wicks, Martina Wiedau, Richard Bedlack\",\"doi\":\"10.1080/21678421.2024.2311721\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>ALSUntangled reviews alternative and off-label treatments on behalf of people with ALS (PALS) who ask about them. Here, we review withania somnifera (WS) commonly known as ashwagandha or winter cherry. WS has plausible mechanisms for slowing ALS progression because of its effects on inflammation, oxidative stress, autophagy, mitochondrial function, and apoptosis. Preclinical trials demonstrate that WS slows disease progression in multiple different animal models of ALS. Of the five individuals we found who described using WS for their ALS, two individuals reported moderate benefit while none reported experiencing any significant side effects. There is currently one clinical trial using WS to treat PALS; the results are not yet published. There are no serious side effects associated with WS and the associated cost of this treatment is low. Based on the above information, WS appears to us to be a good candidate for future ALS trials.</p>\",\"PeriodicalId\":72184,\"journal\":{\"name\":\"Amyotrophic lateral sclerosis & frontotemporal degeneration\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-02-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Amyotrophic lateral sclerosis & frontotemporal degeneration\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/21678421.2024.2311721\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Amyotrophic lateral sclerosis & frontotemporal degeneration","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/21678421.2024.2311721","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

ALSUntangled 代表 ALS 患者 (PALS) 对询问的替代治疗和标签外治疗进行审查。在此,我们对俗称灰树花或冬樱桃的睡茄(WS)进行了评述。由于 WS 对炎症、氧化应激、自噬、线粒体功能和细胞凋亡有影响,因此它在延缓 ALS 病程进展方面具有可信的机制。临床前试验证明,在多种不同的 ALS 动物模型中,WS 都能延缓疾病的进展。在我们找到的五位自述使用 WS 治疗 ALS 的患者中,有两人表示获得了中等程度的治疗效果,没有人表示出现任何明显的副作用。目前有一项使用 WS 治疗 PALS 的临床试验,结果尚未公布。WS 没有严重的副作用,治疗成本也很低。根据上述信息,我们认为 WS 是未来 ALS 试验的理想候选药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
ALSUntangled #74: Withania Somnifera (Ashwagandha).

ALSUntangled reviews alternative and off-label treatments on behalf of people with ALS (PALS) who ask about them. Here, we review withania somnifera (WS) commonly known as ashwagandha or winter cherry. WS has plausible mechanisms for slowing ALS progression because of its effects on inflammation, oxidative stress, autophagy, mitochondrial function, and apoptosis. Preclinical trials demonstrate that WS slows disease progression in multiple different animal models of ALS. Of the five individuals we found who described using WS for their ALS, two individuals reported moderate benefit while none reported experiencing any significant side effects. There is currently one clinical trial using WS to treat PALS; the results are not yet published. There are no serious side effects associated with WS and the associated cost of this treatment is low. Based on the above information, WS appears to us to be a good candidate for future ALS trials.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
ALSUntangled #76: Wahls protocol. Graph theory network analysis reveals widespread white matter damage in brains of patients with classic ALS. Alteration in ornithine metabolism due to mutation in ALDH18A1 masquerading as ALS in pregnancy. Multistep modeling applied to a Malaysian ALS registry. Assessing disease progression in ALS: prognostic subgroups and outliers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1